CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
18F-FDG PET 参数在 CAR-T 细胞治疗下淋巴瘤患者中的预后价值：一项系统评价和 meta 分析
英文原题：The prognostic utility of (18)F-FDG PET parameters in lymphoma patients under CAR-T-cell therapy: a systematic review and meta-analysis.
查看英文原题
The prognostic utility of (18)F-FDG PET parameters in lymphoma patients under CAR-T-cell therapy: a systematic review and meta-analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
[ 18 F]FDG PET 参数是预测接受 CAR-T 细胞治疗的淋巴瘤患者结局的有价值预后工具。
研究思路结论见上方概要
背景
嵌合抗原受体（CAR）T细胞疗法自最近获得美国食品药品监督管理局批准以来，已引起广泛关注，因为它已成为肿瘤学领域中一种有前景的免疫治疗模式。本研究探讨了[18F]氟脱氧葡萄糖正电子发射断层扫描（[18F]FDG PET）在接受CAR-T 细胞治疗的淋巴瘤患者中的预后价值。通过荟萃分析，计算了特定PET指标在此背景下的汇总风险比（HR）值。
方法
检索了PubMed、Scopus和Ovid数据库以寻找相关主题。数据集检索从建库至2024年3月12日进行。主要终点是特定PET指标对治疗前后总生存期（OS）和无进展生存期（PFS）的影响。使用Stata 17.0提取研究数据进行meta分析。
结果
在系统评价确定的27项研究中，15项符合meta分析标准。基线OS分析显示，总代谢肿瘤体积（TMTV）的HR最高，为2.66（95% CI：1.52-4.66），其次是全身总病灶糖酵解（TTLG），为2.45（95% CI：0.98-6.08），最大标准化摄取值（SUVmax）为1.30（95% CI：0.77-2.19）。TMTV和TTLG具有统计学显著性（p < 0.0001），而SUVmax则无统计学显著性（p = 0.33）。对于PFS，TMTV同样显示出最高的HR，为2.65（95% CI：1.63-4.30），TTLG为2.35（95% CI：1.40-3.93），SUVmax为1.48（95% CI：1.08-2.04），均具有统计学显著性（p 0.01）。SUVmax是PFS的显著预测因子，HR为2.05（95% CI：1.13-3.69，p = 0.015）。
展开英文摘要原文
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy has attracted considerable attention since its recent endorsement by the Food and Drug Administration, as it has emerged as a promising immunotherapeutic modality within the landscape of oncology. This study explores the prognostic utility of [ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F]FDG PET) in lymphoma patients undergoing CAR T-cell therapy. Through meta-analysis, pooled hazard ratio (HR) values were calculated for specific PET metrics in this context.
METHODS
PubMed, Scopus, and Ovid databases were explored to search for relevant topics. Dataset retrieval from inception until March 12, 2024, was carried out. The primary endpoints were impact of specific PET metrics on overall survival (OS) and progression-free survival (PFS) before and after treatment. Data from the studies were extracted for a meta-analysis using Stata 17.0.
RESULTS
Out of 27 studies identified for systematic review, 15 met the criteria for meta-analysis. Baseline OS analysis showed that total metabolic tumor volume (TMTV) had the highest HR of 2.66 (95% CI: 1.52-4.66), followed by Total-body total lesion glycolysis (TTLG) at 2.45 (95% CI: 0.98-6.08), and maximum standardized uptake values (SUVmax) at 1.30 (95% CI: 0.77-2.19). TMTV and TTLG were statistically significant ( p < 0.0001), whereas SUVmax was not ( p = 0.33). For PFS, TMTV again showed the highest HR at 2.65 (95% CI: 1.63-4.30), with TTLG at 2.35 (95% CI: 1.40-3.93), and SUVmax at 1.48 (95% CI: 1.08-2.04), all statistically significant ( p 0.01). The SUVmax was a significant predictor for PFS with an HR of 2.05 (95% CI: 1.13-3.69, p = 0.015).
CONCLUSION
[ 18 F]FDG PET parameters are valuable prognostic tools for predicting outcome of lymphoma patients undergoing CAR T-cell therapy.
论文信息
- 作者
- Al-Ibraheem A、Abdlkadir AS、Al-Adhami DA、Sathekge M、Bom HH、Ma'koseh M、Mansour A、Abdel-Razeq H
- 第一作者单位
- Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman, Jordan.
- 通讯作者单位
- Nuclear Medicine Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.Italy
- 文献类型
- 系统综述 · 荟萃分析
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39286245 · DOI 10.3389/fimmu.2024.1424269
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →